Oct 25 (Reuters) - Recce Pharmaceuticals Ltd (RCE) :
- RECCE PHARMACEUTICALS ANNOUNCES SAFETY COMMITTEE APPROVES FASTER INFUSION RATE IN PHASE I/II TRIAL OF RECCE® 327 FOR URINARY TRACT INFECTIONS AND UROSEPSIS
- RECCE PHARMACEUTICALS - R327 WAS SHOWN TO BE SAFE & WELL-TOLERATED IN HEALTHY SUBJECTS AT PREVIOUS INFUSION RATES OF 1 HOUR AND 30 MINUTES OF 3,000MG
- RECCE PHARMACEUTICALS LTD - SUBJECT RECRUITMENT IN NEXT COHORT IS WELL UNDERWAY, WITH DOSING TO BEGIN IMMINENTLY
News: RCE Recce Pharma Says Safety Committee Approves Faster Infusion Rate In Phase I/II Trial Of...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $108.4M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 36.5¢ | $39.00K | 102.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9999 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 2108 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| RCE (ASX) Chart |